59206
document
Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia : randomized , double-blind , placebo-controlled study . We aimed to evaluate the efficacy of memantine add-on in the treatment of primary negative symptoms of patients with stable schizophrenia . In a double-blind placebo-controlled clinical trial , 40 patients with schizophrenia ( Diagnostic and Statistical Manual of Mental Disorders , Fourth Edition ) who were stabilized on risperidone for a minimum of 8 weeks were randomized to either memantine ( 20 mg ) or placebo in addition to risperidone , 6 mg/d , for eight weeks . Assessment was done using the Positive and Negative Syndrome Scale at baseline , week 4 , and week 8 . The Hamilton Depression Rating Scale and the Extrapyramidal Symptom Rating Scale at baseline and week 8 were used to assess depression and extrapyramidal symptoms , respectively . All 40 patients had at least one postbaseline measurement , and 38 patients completed the trial . Patients in the memantine group showed a significantly greater improvement on negative subscale than the placebo group at end point ( P < 0.001 ) . The same effect was observed for the total score ( P < 0.001 ) and the general psychopathology subscale score ( P = 0.002 ) . There was no significant difference in reduction of positive symptoms score between the 2 groups ( P = 0.757 ) . Changes in the Hamilton Depression Rating Scale and the Extrapyramidal Symptom Rating Scale scores and frequency of adverse effects did not differ between the 2 groups . Our study showed that memantine is a tolerable and efficacious add-on treatment for primary negative symptoms of schizophrenia .
59207
Intervention_Pharmacological
Memantine add-on to risperidone
59208
Intervention_Pharmacological
memantine
59209
Intervention_Pharmacological
risperidone
59210
Intervention_Pharmacological
memantine
59211
Intervention_Control
placebo
59212
Intervention_Pharmacological
risperidone
59213
Intervention_Control
placebo
59214
Outcome_Mental
Positive and Negative Syndrome Scale
59215
Outcome_Mental
Hamilton Depression Rating Scale
59216
Outcome_Mental
the Extrapyramidal Symptom Rating Scale
59217
Outcome_Other
significantly greater
59218
Outcome_Mental
improvement on negative subscale
59219
Outcome_Other
same effect
59220
Outcome_Mental
general psychopathology subscale score
59221
Outcome_Other
no significant difference
59222
Outcome_Other
reduction of positive symptoms score
59223
Outcome_Mental
Hamilton Depression Rating Scale
59224
Outcome_Mental
Extrapyramidal Symptom Rating Scale
59225
Participant_Condition
stable schizophrenia
59226
Participant_Condition
stable schizophrenia
59227
Participant_Sample-size
40
59228
Participant_Condition
schizophrenia
59229
Participant_Sample-size
40
59230
Participant_Sample-size
38